Akeso, Inc. (HKG:9926)
Hong Kong · Delayed Price · Currency is HKD 87.55
+3.65 (4.35%)
Jun 18, 2026, 4:08 PM HKT
Akeso Earnings Call Transcripts
Fiscal Year 2024
-
2024 saw strong revenue growth, major drug approvals, and strategic NRDL inclusion for key bispecific antibodies, supported by robust clinical data and pipeline expansion. Operating losses narrowed, and the company is well-capitalized for further growth and global partnerships.
-
Management highlighted an $8B Hong Kong valuation, global expansion plans, and key clinical milestones for ivonescimab and cadonilimab. Proprietary bispecific antibody technology and a robust pipeline support ambitions beyond China, with major data readouts expected by 2026.